Introduction
Cardiovascular disease is exceptionally common among patients with chronic kidney disease (CKD), including those treated with dialysis, and accounts for nearly half of deaths in such patients [1] [2] [3] . Cardiovascular events in patients with CKD and end-stage renal disease (ESRD) reflect a range of underlying pathological processes. Hypertension and diabetes mellitus (DM) are prevalent and often severe, but these and other classical cardiovascular risks such as smoking and dyslipidemia do not adequately account for the high rates of cardiovascular events. Indeed, two large-scale randomized clinical trials (RCTs) in patients on hemodialysis failed to demonstrate a benefit of hydroxymethyl glutaryl-CoA reductase inhibitors ('statins') on the rate of composite cardiovascular end points [4, 5] , although a significant reduction in major atherosclerotic events following treatment with simvastatin plus ezetimibe was recently reported in patients with CKD [6] .
Cardiovascular risk factors linked to CKD include heightened states of inflammation [7, 8] , oxidative stress [8, 9] , activation of the renin-angiotensin-aldosterone [10] [11] [12] and sympathetic nervous [13, 14] systems, endothelial dysfunction [14] [15] [16] , retention of specific promoters of atherosclerosis [17] , abnormalities in platelet aggregation [18] , anemia [18] [19] [20] and disorders of mineral metabolism, including hyperphosphatemia and secondary hyperparathyroidism (sHPT) with persistently high plasma parathyroid hormone (PTH) concentrations [21] [22] [23] . In observational studies of patients on dialysis, elevated serum concentrations of phosphorus, calcium, PTH and fibroblast growth factor 23 have been associated with mortality and cardiovascular events [24] [25] [26] . sHPT per se, and several of the therapeutic interventions used to manage it, can unfavorably alter calcium and phosphorus homeostasis. High serum phosphorus and calcium concentrations are thought to contribute to arterial calcification, with attendant adverse hemodynamic consequences. Results from several RCTs [27] [28] [29] suggest that some therapeutic interventions can attenuate vascular calcification in patients on dialysis yet none of these studies were adequately powered to determine the effect of these strategies on mortality or cardiovascular events.
Treatment of sHPT with cinacalcet decreases circulating PTH concentrations and, unlike treatment with calcitriol and activated vitamin D derivatives, modestly lowers serum calcium and phosphorus concentrations [30] . EValuation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) will test the hypothesis that treatment with cinacalcet compared with placebo (on a background of conventional therapy including phosphate binders +/− vitamin D sterols) reduces time to death or non-fatal cardiovascular events among patients on hemodialysis with sHPT. Herein, we present demographic, clinical and biochemical data at baseline for EVOLVE subjects, with a focus on regional variation.
Materials and methods

Study design
EVOLVE is an ongoing double-blinded placebo-controlled RCT in patients on hemodialysis with sHPT, designed to assess the effect of treatment with cinacalcet versus placebo (in addition to optimal standard therapy) on a primary composite outcome of death or one of several major cardiovascular events. Components of the composite cardiovascular end point include non-fatal myocardial infarction and hospitalization for unstable angina, heart failure and peripheral arterial disease, the latter including revascularization procedures and non-traumatic amputation. Secondary outcomes include stroke, fracture and surgical parathyroidectomy (PTX). Events are adjudicated by an independent Clinical Endpoints Classification group. EVOLVE is an event-driven trial that will terminate when ∼1882 subjects experience a clinical episode that represents one of the components of the primary composite outcome.
Study population
Study subjects were ≥18 years of age and treated with hemodialysis or hemodiafiltration three times per week for ≥3 months at study entry. Additional eligibility criteria included an intact plasma PTH concentration ≥300 pg/mL (normal range 11-72 pg/mL), a value for the calcium-phosphorus ion product (Ca × P) ≥45 mg 2 /dL 2 when calculated using an albumin-corrected serum calcium concentration and an albumin-corrected serum calcium concentration ≥8.4 mg/dL. We enrolled a total of 3883 subjects from 22 countries, including the USA, Canada, Australia, three Latin American nations, Russia and 15 European nations.
Exclusion criteria included an unstable medical condition (as judged by the investigator), a life-limiting concurrent medical condition, PTX within the previous 12 weeks, an expectation by the investigator that PTX would be required within 6 months after randomization, treatment with cinacalcet within 3 months prior to randomization and hospitalization within 12 weeks for myocardial infarction, unstable angina, heart failure, peripheral arterial disease or stroke. Patients with a history of seizure within 12 weeks prior to randomization, those with a scheduled date for living donor kidney transplantation and those receiving other investigational products within 30 days prior to randomization were also excluded.
Blood pressure was measured pre-dialysis using a standard sphygmomanometer. Biochemical determinations at baseline included a plasma PTH concentration, serum concentrations of calcium, phosphorus, Ca × P product, 25-hydroxy vitamin D, 1,25-dihydroxy vitamin D and N-telopeptide (NTx) and serum activity of bone-specific alkaline phosphatase (BALP). All biochemical testing was performed in one of three central laboratories (Covance Inc.). We used an immunometric assay that detects the full-length peptide hormone (PTH 1-84) and various amino-terminally truncated PTH fragments (i.e. intact PTH). 
Statistical analysis
We present continuous results as either mean ± SD or median with 10%, 90% range (to accommodate skewness in some variables) and discrete results as proportions. When comparing differences across regions, we used either analysis of variance or the Kruskal-Wallis test for continuous variables and the χ 2 test for categorical variables. We compared subjects randomized in the USA (n = 1430), Canada (n = 146), Latin America (n = 687), Europe (n = 1188), Russia (n = 283) and Australia (n = 149). To account for the large sample size and multiple comparisons, we considered two-tailed P-values <0.0001 as statistically significant. Statistical analyses were conducted using SAS 9.2 (Cary, NC). Table 1 summarizes demographic and clinical characteristics of EVOLVE subjects stratified by region. The mean age for all study participants was 54 ± 14 years. Subjects in the USA, Canada, Europe and Australia were older than subjects in Russia and Latin America. As expected, the distribution of subjects according to race differed by region. The proportion of blacks was highest in the USA, slightly exceeding 50%, whereas blacks represented <12% of study participants in all other regions.
Results
Demographic and clinical data
The median dialysis vintage among all study participants was 45 (9-146) months. Vascular access varied significantly by region. The proportion of subjects with an arteriovenous fistula was highest in Russia and lowest in Canada and the USA. Synthetic grafts were used more often in the USA, whereas indwelling venous ('permanent') catheters were used more often in Canada.
The prevalence of several cardiovascular diseases among study participants differed significantly by region ( Table 1 ). The proportion of subjects with a history of heart failure was lower in Latin America than in other regions. A history of peripheral arterial disease was reported more frequently in the USA, Canada, Europe and Australia and less frequently in Russia and Latin America. One-third of subjects had DM, with <5% classified as Type I DM and nearly 30% as Type II DM. Type II DM affected >40% of subjects in the USA and Australia and 2.5% of subjects in Russia.
Globally, nearly 20% of study subjects reported a history of skeletal fracture. Surgical PTX had been performed previously in 176 (4.5%) study subjects, indicating refractory or recurrent sHPT.
Biochemical results, globally and by region
General laboratory results. Laboratory variables stratified by region are outlined in Table 2 . The mean hemoglobin concentration was 11.8 ± 1.5 g/dL; the mean serum albumin was 3.6 ± 0.4 g/dL. Dialysis dose was assessed both by single-pool urea kinetic modeling (spKt/V urea ) and/or measurements of urea reduction ratio (URR). The vast majority of subjects in all regions achieved conventional metrics of adequate hemodialysis (spKt/V urea >1.2 or a URR >65%).
Parameters of chronic kidney disease-mineral bone disorder. The mean serum calcium and phosphorus concentrations were 9.8 ± 0.7 mg/dL and 6.5 ± 1.4 mg/dL. The median plasma PTH concentration for all subjects was 692 pg/mL (10%, 90% range, 363-1694 pg/mL); the mean value was 893 ± 614 pg/mL. The median PTH value was lowest in the USA. Median values for BALP and NTx were 23.0 (11.5-68.1) μg/L and 255 (80-884) nmol bone collagen equivalent/L, respectively. Median values for NTx were highest in Latin America and Russia.
Vitamin D status. The median serum 25-hydroxy vitamin D concentration globally was 17 ng/mL (10%, 90% range, 8-37 pg/mL) with values highest in Latin America. The median serum concentration of 1,25-dihydroxy vitamin D (calcitriol) was 8.8 ng/mL (10%, 90% range, 5.0-23.5 pg/mL).
Of 3789 subjects with results available for serum 25-hydroxy vitamin D, 3019 (80%) subjects had either vitamin D insufficiency (n = 1546) or vitamin D deficiency (n = 1473). Forty-nine (1%) subjects had severe vitamin D deficiency (25-hydroxy vitamin D concentrations <5 ng/mL). Notably, 61% of subjects with biochemical evidence of inadequate vitamin D stores were receiving calcitriol or activated vitamin D derivatives at baseline.
Chronic kidney disease-mineral bone disorder medication use Table 3 shows selected medication prescription, also stratified by region. Table 4 shows the same among the individual European nations. Overall, 87% of subjects were prescribed phosphate binders at baseline. Over half of all subjects were receiving treatment with calcitriol or one of its synthetic derivatives; the proportion was lowest in Latin America. Intravenous active vitamin D derivatives were used much more frequently in the USA than in Canada, Europe or other regions. Overall, nutritional vitamin D supplements were used much less frequently. Only 114 subjects, or 2.9%, of all study participants were receiving ergocalciferol or cholecalciferol at baseline. Vitamin D use varied among the 15 European nations; Germany was the only country in which a sizeable fraction of subjects were prescribed nutritional vitamin D supplements.
Cardiovascular medication use
Overall, baseline prescription of beta-adrenergic antagonists, angiotensin-converting enzyme-inhibitors or angiotensin receptor blockers, aspirin/clopidogrel and statins was 47, 44, 36 and 33%, respectively, with substantial variability across regions (Table 3 ).
Discussion
The current results contain robust contemporary information with a global perspective about the clinical and biochemical features of patients on hemodialysis with sHPT and provide an overview of the therapeutics commonly used to control the disorder. By design, EVOLVE enrolled subjects with biochemical evidence of sHPT, as judged by plasma PTH concentrations ≥300 pg/mL without consideration of prior treatments. The finding that the median plasma PTH concentration at baseline was nearly 700 pg/mL (with >10% above 1600 pg/mL) and that the mean PTH value was nearly 900 pg/mL which indicates that many participants in EVOLVE had advanced sHPT at study entry. Nevertheless, more than onethird of subjects had baseline PTH concentrations between 300 and 600 pg/mL, indicating that subjects with less advanced sHPT were also adequately represented and that the full spectrum of sHPT was included in EVOLVE.
Several factors could explain regional differences in sHPT severity including differences in age, race/ethnicity, dialysis vintage, the proportion of subjects with diabetes, practice patterns of selection of dialysis candidates and other geographic considerations such as diet and nutritional vitamin D intake. Latitude and sunlight exposure are known to affect endogenous production of vitamin D in the general population. Differences in sun exposure could explain some of the regional variation in PTH but are unlikely to explain higher PTH concentrations in Latin America. Differences in hemodialysis practice patterns including variations in dialysate calcium concentration and the use of prescription and non-prescription drugs, including vitamin D sterols and phosphate-binding agents, may also have contributed to regional differences in biochemical parameters. Additionally, in some regions, health system and financial constraints could have limited access to some therapeutic agents in patients with chronic kidney disease-mineral bone disorder (CKD-MBD).
The results herein highlight the global nature of nutritional vitamin D deficiency among patients with ESRD and the need to better understand its causes and consequences. Potential reasons for this finding are many. The dietary intake of milk and other dairy products, which serve as primary sources of ingested vitamin D in some countries, is often restricted among patients with little or no residual kidney function as part of broader efforts to limit dietary phosphorus intake and manage hyperphosphatemia. Oral multivitamin preparations that are widely used in the hemodialysis population do not contain fatsoluble vitamins, including vitamin D. The prevalence of frailty among patients on dialysis is high [31, 32] and patients typically have one or more comorbid medical conditions that constrain outdoor activities and thus limit cumulative sunlight exposure, further compromising the endogenous production of 25-hydroxy vitamin D in skin. Light-skinned persons on dialysis have more skin pigmentation because a variety of chromogens are retained in plasma and subsequently deposited in skin when residual kidney function is markedly impaired [33] . Blacks represent a disproportionately large proportion of the dialysis population in the USA (and approximately half of US Comparisons across all regions were significant at P < 0.0001 except for sex. a EVOLVE subjects), and the capacity to produce 25-hydroxy vitamin D from skin during exposure to sunlight is diminished in blacks compared to other racial groups [34] . Mechanisms to account for lower serum 25-hydroxy vitamin D levels among subjects treated with calcitriol and other vitamin D analogs have been previously Table 3 . Selected medication use at baseline a Comparisons across all regions were significant at P < 0.0001. IV, Intravenous; PO, Oral. described [35, 36] . Calcitriol is known to upregulate expression of the 24-hydroxylase enzyme (CYP24B) in kidney, an adaptive response that serves to degrade calcitriol and other metabolites of vitamin D, including 25-hydroxy vitamin D, to form compounds with less biological activity [37] . The observation that one-fifth of all EVOLVE study subjects reported a history of skeletal fracture was not entirely unexpected considering the severity of sHPT in EVOLVE. Understanding the relations among the severity of sHPT, bone loss and risk of skeletal fracture at baseline for participants is challenging, as enrollment was not confined to previously untreated patients with overt sHPT, and data on the timing of fracture were incomplete. Results from observational studies indicate an increased prevalence of fractures in patients with CKD [38, 39] , but the reason(s) for the increased risk is unclear. In animal studies, biomechanical testing has shown decreased fragility (i.e. improved bone strength) with treatment of sHPT [40] but there is little information about the reasons for the higher fracture risk among patients with CKD/ESRD and the specific role of sHPT. The duration of 'predialysis' CKD, dialysis vintage and prior medical or surgical treatment of sHPT influence plasma PTH concentrations and other biomarkers of disease severity [41] .
The observation that 5% of subjects in EVOLVE had previously undergone PTX offers further evidence of the progressive nature of sHPT. In the past, 15-30% of patients undergoing subtotal PTX for the management of sHPT were reported to develop recurrent disease. Few studies have addressed this issue recently, but high rates of disease recurrence would not be unexpected. Clonal tumor-like cell proliferation has been documented among patients with longstanding sHPT and severe parathyroid gland hyperplasia and apoptosis rates in parathyroid tissue are extremely low [42] . Indeed, the half-life of parathyroid cells has been estimated to be ∼31 years [43] . Important fundamental disturbances in cell-cycle regulation of parathyroid tissue are likely to contribute not only to the high rate of disease recurrence after PTX [44] but also to disease progression. Surgical approaches to PTX also differ around the world, with surgeons in some countries preferentially performing 'total' PTX whereas 'subtotal' PTX is more common in the USA.
Herein, we also document the substantial burden of cardiovascular disease among patients on hemodialysis with sHPT. Evidence of overt cardiovascular disease in certain geographic regions such as Russia and Latin America, where the proportion of patients with diabetes was considerably less and the cohort younger than in Canada and the USA, suggests that sHPT per se, some of the treatments given to control sHPT, and potentially other CKDrelated cardiovascular risk factors contribute to cardiovascular risk in the broader hemodialysis population.
In summary, among study subjects enrolled in the EVOLVE trial, we found a substantial burden of pre-existing cardiovascular disease and other manifestations of CKD-MBD, including fractures, prior PTX and ongoing disturbances in calcium and phosphorus metabolism despite active management of these disorders. The burden of some pre-existing cardiovascular diseases and baseline laboratory abnormalities including several proxies of bone turnover differed substantially across study regions. EVOLVE will compare the effects of cinacalcet versus placebo in addition to traditional therapy for sHPT including phosphate binders and vitamin D sterols on a primary composite outcome of mortality and major cardiovascular events. The effect of cinacalcet on several secondary outcomes, including PTX and fracture, will also be examined.
